These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 19507253)
1. Upregulation of manganese superoxide dismutase (SOD2) is a common pathway for neuroendocrine differentiation in prostate cancer cells. Quirós I; Sáinz RM; Hevia D; García-Suárez O; Astudillo A; Rivas M; Mayo JC Int J Cancer; 2009 Oct; 125(7):1497-504. PubMed ID: 19507253 [TBL] [Abstract][Full Text] [Related]
2. MnSOD drives neuroendocrine differentiation, androgen independence, and cell survival in prostate cancer cells. Quiros-Gonzalez I; Sainz RM; Hevia D; Mayo JC Free Radic Biol Med; 2011 Feb; 50(4):525-36. PubMed ID: 21056653 [TBL] [Abstract][Full Text] [Related]
3. Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells. Yuan TC; Veeramani S; Lin MF Endocr Relat Cancer; 2007 Sep; 14(3):531-47. PubMed ID: 17914087 [TBL] [Abstract][Full Text] [Related]
4. Release of macrophage migration inhibitory factor by neuroendocrine-differentiated LNCaP cells sustains the proliferation and survival of prostate cancer cells. Tawadros T; Alonso F; Jichlinski P; Clarke N; Calandra T; Haefliger JA; Roger T Endocr Relat Cancer; 2013 Feb; 20(1):137-49. PubMed ID: 23207293 [TBL] [Abstract][Full Text] [Related]
5. Neuroendocrine differentiation in prostate carcinoma: focusing on its pathophysiologic mechanisms and pathological features. Alberti C G Chir; 2010; 31(11-12):568-74. PubMed ID: 21232206 [TBL] [Abstract][Full Text] [Related]
6. Isoform 1 of TPD52 (PC-1) promotes neuroendocrine transdifferentiation in prostate cancer cells. Moritz T; Venz S; Junker H; Kreuz S; Walther R; Zimmermann U Tumour Biol; 2016 Aug; 37(8):10435-46. PubMed ID: 26846108 [TBL] [Abstract][Full Text] [Related]
7. SRC family kinase FYN promotes the neuroendocrine phenotype and visceral metastasis in advanced prostate cancer. Gururajan M; Cavassani KA; Sievert M; Duan P; Lichterman J; Huang JM; Smith B; You S; Nandana S; Chu GC; Mink S; Josson S; Liu C; Morello M; Jones LW; Kim J; Freeman MR; Bhowmick N; Zhau HE; Chung LW; Posadas EM Oncotarget; 2015 Dec; 6(42):44072-83. PubMed ID: 26624980 [TBL] [Abstract][Full Text] [Related]
9. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression. Cox ME; Deeble PD; Lakhani S; Parsons SJ Cancer Res; 1999 Aug; 59(15):3821-30. PubMed ID: 10447001 [TBL] [Abstract][Full Text] [Related]
10. Adrenomedullin, an autocrine/paracrine factor induced by androgen withdrawal, stimulates 'neuroendocrine phenotype' in LNCaP prostate tumor cells. Berenguer C; Boudouresque F; Dussert C; Daniel L; Muracciole X; Grino M; Rossi D; Mabrouk K; Figarella-Branger D; Martin PM; Ouafik L Oncogene; 2008 Jan; 27(4):506-18. PubMed ID: 17637748 [TBL] [Abstract][Full Text] [Related]
11. Up-Regulated Expression of LAMP2 and Autophagy Activity during Neuroendocrine Differentiation of Prostate Cancer LNCaP Cells. Morell C; Bort A; Vara-Ciruelos D; Ramos-Torres Á; Altamirano-Dimas M; Díaz-Laviada I; Rodríguez-Henche N PLoS One; 2016; 11(9):e0162977. PubMed ID: 27627761 [TBL] [Abstract][Full Text] [Related]
12. Regulation of interleukin-6-mediated PI3K activation and neuroendocrine differentiation by androgen signaling in prostate cancer LNCaP cells. Xie S; Lin HK; Ni J; Yang L; Wang L; di Sant'Agnese PA; Chang C Prostate; 2004 Jun; 60(1):61-7. PubMed ID: 15129430 [TBL] [Abstract][Full Text] [Related]
13. Autophagy pathway is required for IL-6 induced neuroendocrine differentiation and chemoresistance of prostate cancer LNCaP cells. Chang PC; Wang TY; Chang YT; Chu CY; Lee CL; Hsu HW; Zhou TA; Wu Z; Kim RH; Desai SJ; Liu S; Kung HJ PLoS One; 2014; 9(2):e88556. PubMed ID: 24551118 [TBL] [Abstract][Full Text] [Related]
14. Gene profiling and pathway analysis of neuroendocrine transdifferentiated prostate cancer cells. Mori R; Xiong S; Wang Q; Tarabolous C; Shimada H; Panteris E; Danenberg KD; Danenberg PV; Pinski JK Prostate; 2009 Jan; 69(1):12-23. PubMed ID: 18814146 [TBL] [Abstract][Full Text] [Related]
15. Multipathways for transdifferentiation of human prostate cancer cells into neuroendocrine-like phenotype. Zelivianski S; Verni M; Moore C; Kondrikov D; Taylor R; Lin MF Biochim Biophys Acta; 2001 May; 1539(1-2):28-43. PubMed ID: 11389966 [TBL] [Abstract][Full Text] [Related]
16. MnSOD upregulation sustains the Warburg effect via mitochondrial ROS and AMPK-dependent signalling in cancer. Hart PC; Mao M; de Abreu AL; Ansenberger-Fricano K; Ekoue DN; Ganini D; Kajdacsy-Balla A; Diamond AM; Minshall RD; Consolaro ME; Santos JH; Bonini MG Nat Commun; 2015 Feb; 6():6053. PubMed ID: 25651975 [TBL] [Abstract][Full Text] [Related]
17. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression. Lee SO; Chun JY; Nadiminty N; Lou W; Gao AC Prostate; 2007 May; 67(7):764-73. PubMed ID: 17373716 [TBL] [Abstract][Full Text] [Related]
18. MnSOD up-regulates maspin tumor suppressor gene expression in human breast and prostate cancer cells. Duan H; Zhang HJ; Yang JQ; Oberley LW; Futscher BW; Domann FE Antioxid Redox Signal; 2003 Oct; 5(5):677-88. PubMed ID: 14580325 [TBL] [Abstract][Full Text] [Related]